Navidea Biopharmaceuticals (NAVB) Institutional Ownership → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free NAVB Stock Alerts $0.04 +0.00 (+1.33%) (As of 04/26/2024 08:54 PM ET) Add Compare Share Share OwnershipStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Institutional Ownership Changes (13F Filings) for Navidea Biopharmaceuticals (NYSE:NAVB)CurrentInstitutional OwnershipPercentage0.01%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$11.85KNumber ofInstitutional Sellers(last 12 months)0 Get NAVB Insider Trade Alerts Want to know when executives and insiders are buying or selling Navidea Biopharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data NAVB Institutional Buying and Selling by Quarter Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. Navidea Biopharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails7/20/2023 Allred Capital Management LLC293,838$27K0.0%+78.4%0.838% 1/31/2022Commonwealth Equity Services LLC51,203$51K0.0%N/A0.170% 1/25/2022 Allred Capital Management LLC53,238$53K0.0%-18.1%0.176% 10/12/2021 Allred Capital Management LLC64,988$114K0.1%-11.9%0.215% 8/17/2021Bridgeway Capital Management LLC102,440$187K0.0%-49.4%0.340% 8/16/2021State Street Corp23,843$44K0.0%N/A0.079% 8/13/2021Geode Capital Management LLC97,206$177K0.0%+29.4%0.322% 8/6/2021HighTower Advisors LLC28,465$51K0.0%+84.1%0.098% 8/5/2021 Allred Capital Management LLC73,788$135K0.1%+15.3%0.254% 5/19/2021Squarepoint Ops LLC28,836$58K0.0%N/A0.099% 5/13/2021Renaissance Technologies LLC131,618$266K0.0%+136.3%0.461% 5/10/2021HighTower Advisors LLC15,465$33K0.0%-57.1%0.054% 5/6/2021 Allred Capital Management LLC64,003$129K0.1%+20.9%0.224% 2/10/2021Renaissance Technologies LLC55,695$120K0.0%-42.1%0.209% 2/10/2021HighTower Advisors LLC36,065$79K0.0%+14.1%0.135% 1/21/2021 Allred Capital Management LLC52,926$113K0.1%-19.0%0.198% 8/31/2020Bridgeway Capital Management Inc.62,540$246K0.0%N/A0.242% 8/10/2020HighTower Advisors LLC27,540$109K0.0%+82.5%0.108% 8/7/2020Virtu Financial LLC17,586$69K0.0%N/A0.069% 7/16/2020OTA Financial Group L.P.65,600$258K0.3%N/A0.279% 7/10/2020FNY Investment Advisers LLC105,000$413K0.2%-47.4%0.446% (Data available from 1/1/2016 forward) NAVB Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of NAVB shares? During the previous two years, the following institutional investors and hedge funds held shares of Navidea Biopharmaceuticals shares: Allred Capital Management LLC ($27K).Learn more on NAVB's institutional investors. What percentage of Navidea Biopharmaceuticals stock is owned by institutional investors? 0.01% of Navidea Biopharmaceuticals stock is owned by institutional investors. Learn more on NAVB's institutional investor holdings. Which institutional investors have been buying Navidea Biopharmaceuticals stock? The following institutional investors have purchased Navidea Biopharmaceuticals stock in the last 24 months: Allred Capital Management LLC ($129.10K). How much institutional buying is happening at Navidea Biopharmaceuticals? Institutional investors have bought a total of 129,100 shares in the last 24 months. This purchase volume represents approximately $11.85K in transactions. Related Companies: MyMD Pharmaceuticals Institutional Ownership Virax Biolabs Group Institutional Ownership Biomerica Institutional Ownership GeoVax Labs Institutional Ownership NexImmune Institutional Ownership IMAC Institutional Ownership MDxHealth Institutional Ownership SenesTech Institutional Ownership Data Knights Acquisition Institutional Ownership Revelation Biosciences Institutional Ownership This page (NYSE:NAVB) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHis win rate puts Warren Buffett to shame… Investing DailyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryHas Jeff Bezos Found the Next Nvidia?InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.